Drug intelligence / Profile preview

fulvestrant + gefitinib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

A combination therapy consisting of fulvestrant, a selective estrogen receptor downregulator (SERD), and gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination targets both estrogen receptor (ER) signaling and EGFR pathways simultaneously, exploiting the cross-talk between these pathways. Preclinical studies have shown enhanced antitumor effects compared to either drug alone, particularly in non-small cell lung cancer (NSCLC) cells with acquired resistance to gefitinib.

Brand names: IressaFaslodex
Other names: ZD1839 (for gefitinib)ICI 182,780 (for fulvestrant)

Targets

EGFR (Epidermal growth factor receptor)ESR1 (ERα)

Beyond the preview

Go deeper on fulvestrant + gefitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + gefitinib.

Explore the full profile